Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor

International Journal of Laboratory Hematology

Volumn 37, Issue 4, 2015, Pages 521-529

  Shenkman, B ^a   Einav, Y ^b   Livnat, T ^a   Budnik, I ^c   Martinowitz, U ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b HOLON INSTITUTE OF TECHNOLOGY   (Israel)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

FEIBA; TAFI; Fibrinogen; Thrombocytopenia; Thromboelastometry

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; CALCIUM CHLORIDE; FIBRINOGEN CONCENTRATE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; BLOOD CLOTTING FACTOR; FIBRINOGEN; PROTHROMBIN COMPLEX CONCENTRATES;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD EXAMINATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; HEMATOLOGICAL PROCEDURE; HEMODILUTION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; ROTATION THROMBOELASTOMETRY; THROMBOCYTOPENIA; BIOLOGICAL MODEL; BLOOD; BLOOD CLOTTING TEST; CYTOLOGY; DEVICES; DRUG EFFECTS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; ROTATION; SEVERITY OF ILLNESS INDEX; THROMBOCYTE; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CALCIUM CHLORIDE; CARBOXYPEPTIDASE B2; FIBRINOGEN; HUMANS; MODELS, BIOLOGICAL; PRIMARY CELL CULTURE; ROTATION; SEVERITY OF ILLNESS INDEX; THROMBELASTOGRAPHY; THROMBOCYTOPENIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84948089398     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12331     Document Type: Article

References (31)

1. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004;18:153-67.
2. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011;9:262-73.
3. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8.
4. Hardy JF, de Moerloose P, Samama CM; Members of the Groupe d'Intérêt en Hémostase Périopératoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2006;53:S40-58.
5. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant 2006;25:1344-52.
6. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010;104:318-25.
7. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
8. Salley GP. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011;37:621-30.
9. Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost 2008;100:762-5.
10. Wrobel G, Dobaczewski G, Patkowski D, Sokol A, Grotthus E. Experiments with recvombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006;47:729-30.
11. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klinger A, Klima SG, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007;5:1019-25.
12. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009;108:751-8.
13. Misgav M, Shenkman B, Budnik I, Einav Y, Martinowitz U. Distinct effects of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia. Anesth Analg 2011;112:1034-40.
14. Aledort IM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008;14:39-43.
15. Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011;45:990-9.
16. Aledort L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-8.
17. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:2792-8.
18. Wang W, Roffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-81.
19. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366-75.
20. Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Störkson R, Hervig T. Thromboelastography. Transfus Apher Sci 2009;40:119-23.
21. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thromboelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008;100:792-7.
22. Larsen OH, Ingerslev J, Sorensen B. Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions. Am Hematol 2007;86:217-21.
23. Shenkman B, Livnat T, Lubetski A, Tamarin I, Budnik I, Einav Y, Martinowitz U. The in vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model. Blood Coagul Fibrinolysis 2012;23:370-8.
24. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006;12:598-604.
25. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009;15:904-10.
26. Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation 2013;128:1179-81.
27. Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia 2012;18:544-9.
28. Declerck PJ. Thrombin activatable fibrinolysis inhibitor. Hemostaseologie 2011;31:165-73.
29. Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N, Colucci M. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood. J Thromb Haemost 2011;8:154-62.
30. Fries D, Haas T, Klingler A, Streif W, Kilma G, Martini J, Wagner-Berger H, Innerhofer P. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy - a porcine model. Br J Anaesth 2006;97:460-7.
31. Schöchl H, Forster L, Woidke R, Solomon C, Voelckel W. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate. Anaesthesia 2009;65:199-203.